CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Transcranial magnetic stimulationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04604210
NCT04604210Phase 2Completed
CompareCT.gov

A Pilot Randomized Trial of Distinct Symptom-specific Targets for Transcranial Magnetic Stimulation in Patients With Depression and Anxiety

Brigham and Women's Hospital·interventional·Posted Oct 27, 2020·Updated Aug 1, 2024

In Brief

A Phase 2 clinical trial evaluating Transcranial magnetic stimulation for Depression and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This pilot study aims to compare two different treatment targets for transcranial magnetic stimulation, an FDA-approved treatment for major depressive disorder (MDD), in terms of their relative efficacy for depression versus anxiety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Anxiety, Major Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 27, 2020
Enrollment StartFeb 3, 2021
Primary CompletionDec 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.7 years ago

Interventions

Transcranial magnetic stimulationprocedure

Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.